Rvnc stock news: robbins llp reminds revance therapeutics, inc. investors of the pending lead plaintiff deadline – march 4, 2025

San diego, feb. 18, 2025 (globe newswire) -- robbins llp reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired revance therapeutics, inc. (nasdaq: rvnc) securities between february 29, 2024 and december 6, 2024. revance is a biotechnology company that develops, manufactures, and commercializes neuromodulators for various aesthetic and therapeutic indications in the u.s. and internationally.
RVNC Ratings Summary
RVNC Quant Ranking